Client Integration Talking Points and FAQ
November 7, 2023
Impact: Legacy Magellan Rx clients [Commercial Employer groups]
In December 2022, we shared the exciting news that Prime Therapeutics LLC (Prime) acquired Magellan Rx management (MRx).
Together, we collectively serve 92 million members across all market segments. With our combined strength and best-in-class teams, we are positioned to transform the industry and deliver even more value to those we serve. Now more than ever, we’re focused on creating a brighter future for you, our valued clients, and your members.
Together, our team includes some of the brightest, boldest and most innovative people in health care. We value your partnership and are committed to keeping you informed as we fully integrate. Our goal is to ensure a smooth transition with minimal disruption to you and your members.
One thing that won’t change is our true partnership approach that puts you and your members at the center of everything we do. Currently, we’re assessing our complementary assets, expertise, capabilities and product offerings in order to create a vibrant new alternative that is greater than the sum of its parts.
As part of an ongoing effort to better serve our clients and their members, we have undergone some enhancements to our combined organizations and account management structure this year.
In August, we announced that Mostafa Kamal would succeed Ken Paulus as President and CEO of Prime Therapeutics. He currently serves as president of Prime Therapeutics, and the CEO of Magellan Rx. His new role elevates him to include leadership of the entire organization.
Provided is an FAQ document that provides an overview of what’s to to come and next steps. Additional information will be shared as these changes near for impacted clients.